Immunomodulatory Drug CC-4047 is a Cell-type and Stimulus-Selective Transcriptional Inhibitor of Cyclooxygenase 2
Gregory D. Ferguson(Ferring Pharmaceuticals (United Kingdom)), Kyle Chan, Kristen Jensen-Pergakes, Dominique Verhelle(Pfizer (United States)), Christopher Morris(University of South Florida), Weilin Xie, Laura G. Corral, Laure Moutouh de Parseval(Bristol-Myers Squibb (Switzerland)), Helen Brady, Normand Richard(Bristol-Myers Squibb (Switzerland)), Candice Wilkey(Bristol-Myers Squibb (Switzerland))
Cited by 32
Related Papers
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
|Cancer Research|2007|232
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
|Journal of Clinical Investigation|2008|180